SMC Update - November 2023
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Progesterone vaginal capsules (Utrogestan®) has been rejected for use in the prevention of preterm birth in women with a singleton pregnancy who have a short cervix and/or a history of spontaneous preterm birth. The manufacturer failed to make a submission for this indication.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
« CKS Updates - October 2023 | NICE Guidance - November 2023 » |
Leave a Comment